Project Grant 0749884

This National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I award to Bactria Pharmaceuticals LLC is providing $274,937 to develop therapeutic drugs that restore antibiotic sensitivity in bacteria that cause severe healthcare-associated infections. The goal is to combat antimicrobial resistance in gram-negative pathogens through the use of small molecule efflux pump inhibitors (EPIs). The project involves three key activities: cryo-electron microscopy to understand...

This Project Grant award from the National Institute of General Medical Sciences (CFDA 93.859 Biomedical Research and Research Training program) provides $460,166 to Ohio University to engineer a platform using genetically modified Lactococcus lactis bacteria capable of expressing biosynthetic gene clusters encoding bioactive natural products. The goal is to enable in situ drug production and targeted delivery of therapeutic lasso peptides, specifically focusing on the anti-diabetic and...

This $275,000 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program supports the development of a label-free, high-resolution, high-throughput protein screening platform called Vibrational Spectroscopy with Metasurface Optics (VISMO). The technology aims to enable simultaneous, minute-scale measurement of millions of protein samples, which would dramatically improve the lengthy and costly cycles...

This $306,872 Phase 1 SBIR grant from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), aims to establish a platform for rapidly developing therapeutic protein binders. The award to Peptiforge, Inc. will fund the synthesis of testbed libraries of known therapeutic protein scaffolds (Aim 1) and the testing of these libraries against high-value human therapeutic targets (Aim 2). The platform leverages...

This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...

The National Science Foundation awarded Ancilia, Inc. a $255,717 Small Business Technology Transfer Phase I Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084). The grant will support development of phage-resistant bacterial therapeutics from July 2021 through June 2023. The NSF Technology, Innovation, and Partnerships program seeks to advance science, engineering, and technology innovation to address national challenges. Under this award, Ancilia...

This $442,710 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) aims to structurally elucidate novel lanthipeptide natural products produced by marine bacteria and evaluate their antibiotic potential against antimicrobial resistant pathogens. The award supports research to characterize the biosynthesis and substrate specificity of a predicted halogenase enzyme involved in the production of...

This $252,906 National Science Foundation project grant supports the development of scalable manufacturing methods for peptide amphiphile molecules by Amphix Bio Inc. The goal is to advance a safer and more affordable alternative to recombinant proteins currently used in spinal fusion surgeries. Over 500,000 such surgeries are performed annually in the U.S. to treat back and neck pain. While peptide amphiphiles show promise for reducing biological dose needs and offering consistent outcomes,...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $350,027 to Asko Therapeutics, Inc. to develop novel injectable implants capable of providing long-term local controlled release of therapeutic monoclonal antibodies. The goal is to overcome challenges with delivering monoclonal antibody therapeutics to hard-to-reach areas of the body, such as the eye, brain, joints, and...

This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...